ONE UP PSILOCYBIN GUMMIES – BLUE SCHNOZBERRY 2.5G

“The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” said Alan Davis, an adjunct assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine, in a news statement.
“Because most other depression treatments take weeks or months to work and may have undesirable effects, this could be a game changer if these findings hold up in future ‘gold-standard’ placebo-controlled
Today, with a net worth of roughly $400 million accrued through various enterprises, Angermayer is one of the driving forces behind the movement to turn long-shunned psychoactive substances, like the psilocybin derived from so-called magic mushrooms, into approved medications for depression and other mental illnesses. Though he still resolutely won’t touch even a drop of alcohol, he has banded together a team of like-minded entrepreneurs — including Silicon Valley billionaire Peter Thiel — to invest in a handful of startups focused on developing psychedelics.
Psychedelics: Can getting high improve your mental health?
“The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” said Alan Davis, an adjunct assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine, in a news statement.